1
|
Vu LY, Luo D, Johnson K, Denehy ED, Songrady JC, Martin J, Trivedi R, Alsum AR, Shaykin JD, Chaudhary CL, Woloshin EJ, Kornberger L, Bhuiyan N, Parkin S, Jiang Q, Che T, Alilain W, Turner JR, Bardo MT, Prisinzano TE. Searching for Synthetic Opioid Rescue Agents: Identification of a Potent Opioid Agonist with Reduced Respiratory Depression. J Med Chem 2024; 67:9173-9193. [PMID: 38810170 DOI: 10.1021/acs.jmedchem.4c00333] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/31/2024]
Abstract
While in the process of designing more effective synthetic opioid rescue agents, we serendipitously identified a new chemotype of potent synthetic opioid. Here, we report that conformational constraint of a piperazine ring converts a mu opioid receptor (MOR) antagonist into a potent MOR agonist. The prototype of the series, which we have termed atoxifent (2), possesses potent in vitro agonist activity. In mice, atoxifent displayed long-lasting antinociception that was reversible with naltrexone. Repeated dosing of atoxifent produced antinociceptive tolerance and a level of withdrawal like that of fentanyl. In rats, while atoxifent produced complete loss of locomotor activity like fentanyl, it failed to produce deep respiratory depression associated with fentanyl-induced lethality. Assessment of brain biodistribution demonstrated ample distribution of atoxifent into the brain with a Tmax of approximately 0.25 h. These results indicate enhanced safety for atoxifent-like molecules compared to fentanyl.
Collapse
Affiliation(s)
- Loan Y Vu
- Department of Pharmaceutical Sciences, University of Kentucky, Lexington, Kentucky 40506, United States
| | - Dan Luo
- Department of Pharmaceutical Sciences, University of Kentucky, Lexington, Kentucky 40506, United States
- Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, Kentucky 40506, United States
| | - Kai Johnson
- Department of Pharmaceutical Sciences, University of Kentucky, Lexington, Kentucky 40506, United States
| | - Emily D Denehy
- Department of Psychology, University of Kentucky, Lexington, Kentucky 40536, United States
| | - Judy C Songrady
- Department of Pharmaceutical Sciences, University of Kentucky, Lexington, Kentucky 40506, United States
| | - Jocelyn Martin
- Department of Psychology, University of Kentucky, Lexington, Kentucky 40536, United States
| | - Riya Trivedi
- Department of Pharmaceutical Sciences, University of Kentucky, Lexington, Kentucky 40506, United States
| | - Alexia R Alsum
- Department of Pharmaceutical Sciences, University of Kentucky, Lexington, Kentucky 40506, United States
| | - Jakob D Shaykin
- Department of Psychology, University of Kentucky, Lexington, Kentucky 40536, United States
| | - Chhabi Lal Chaudhary
- Department of Pharmaceutical Sciences, University of Kentucky, Lexington, Kentucky 40506, United States
- Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, Kentucky 40506, United States
| | - Eric J Woloshin
- Department of Pharmaceutical Sciences, University of Kentucky, Lexington, Kentucky 40506, United States
| | - Lindsay Kornberger
- Department of Pharmaceutical Sciences, University of Kentucky, Lexington, Kentucky 40506, United States
| | - Nazmul Bhuiyan
- Department of Pharmaceutical Sciences, University of Kentucky, Lexington, Kentucky 40506, United States
- Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, Kentucky 40506, United States
| | - Sean Parkin
- Department of Chemistry, University of Kentucky, Lexington, Kentucky 40506, United States
| | - Qianru Jiang
- Center for Clinical Pharmacology, University of Health Sciences and Pharmacy and Washington University School of Medicine, St. Louis, Missouri 63110, United States
| | - Tao Che
- Center for Clinical Pharmacology, University of Health Sciences and Pharmacy and Washington University School of Medicine, St. Louis, Missouri 63110, United States
| | - Warren Alilain
- Spinal Cord and Brain Injury Research Center (SCoBIRC), College of Medicine, University of Kentucky, Lexington, Kentucky 40536, United States
- Department of Neuroscience, University of Kentucky, Lexington, Kentucky 40536, United States
| | - Jill R Turner
- Department of Pharmaceutical Sciences, University of Kentucky, Lexington, Kentucky 40506, United States
| | - Michael T Bardo
- Department of Psychology, University of Kentucky, Lexington, Kentucky 40536, United States
| | - Thomas E Prisinzano
- Department of Pharmaceutical Sciences, University of Kentucky, Lexington, Kentucky 40506, United States
- Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, Kentucky 40506, United States
| |
Collapse
|
2
|
Lunghini F, Fava A, Pisapia V, Sacco F, Iaconis D, Beccari AR. ProfhEX: AI-based platform for small molecules liability profiling. J Cheminform 2023; 15:60. [PMID: 37296454 DOI: 10.1186/s13321-023-00728-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2022] [Accepted: 05/28/2023] [Indexed: 06/12/2023] Open
Abstract
Off-target drug interactions are a major reason for candidate failure in the drug discovery process. Anticipating potential drug's adverse effects in the early stages is necessary to minimize health risks to patients, animal testing, and economical costs. With the constantly increasing size of virtual screening libraries, AI-driven methods can be exploited as first-tier screening tools to provide liability estimation for drug candidates. In this work we present ProfhEX, an AI-driven suite of 46 OECD-compliant machine learning models that can profile small molecules on 7 relevant liability groups: cardiovascular, central nervous system, gastrointestinal, endocrine, renal, pulmonary and immune system toxicities. Experimental affinity data was collected from public and commercial data sources. The entire chemical space comprised 289'202 activity data for a total of 210'116 unique compounds, spanning over 46 targets with dataset sizes ranging from 819 to 18896. Gradient boosting and random forest algorithms were initially employed and ensembled for the selection of a champion model. Models were validated according to the OECD principles, including robust internal (cross validation, bootstrap, y-scrambling) and external validation. Champion models achieved an average Pearson correlation coefficient of 0.84 (SD of 0.05), an R2 determination coefficient of 0.68 (SD = 0.1) and a root mean squared error of 0.69 (SD of 0.08). All liability groups showed good hit-detection power with an average enrichment factor at 5% of 13.1 (SD of 4.5) and AUC of 0.92 (SD of 0.05). Benchmarking against already existing tools demonstrated the predictive power of ProfhEX models for large-scale liability profiling. This platform will be further expanded with the inclusion of new targets and through complementary modelling approaches, such as structure and pharmacophore-based models. ProfhEX is freely accessible at the following address: https://profhex.exscalate.eu/ .
Collapse
Affiliation(s)
- Filippo Lunghini
- EXSCALATE, Dompé Farmaceutici SpA, Via Tommaso de Amicis 95, 80123, Naples, Italy
| | - Anna Fava
- EXSCALATE, Dompé Farmaceutici SpA, Via Tommaso de Amicis 95, 80123, Naples, Italy
| | - Vincenzo Pisapia
- Professional Service Department, SAS Institute, Via Darwin 20/22, 20143, Milan, Italy
| | - Francesco Sacco
- Professional Service Department, SAS Institute, Via Darwin 20/22, 20143, Milan, Italy
| | - Daniela Iaconis
- EXSCALATE, Dompé Farmaceutici SpA, Via Tommaso de Amicis 95, 80123, Naples, Italy
| | | |
Collapse
|
3
|
Abstract
This paper is the fortieth consecutive installment of the annual anthological review of research concerning the endogenous opioid system, summarizing articles published during 2017 that studied the behavioral effects of molecular, pharmacological and genetic manipulation of opioid peptides and receptors as well as effects of opioid/opiate agonists and antagonists. The review is subdivided into the following specific topics: molecular-biochemical effects and neurochemical localization studies of endogenous opioids and their receptors (1), the roles of these opioid peptides and receptors in pain and analgesia in animals (2) and humans (3), opioid-sensitive and opioid-insensitive effects of nonopioid analgesics (4), opioid peptide and receptor involvement in tolerance and dependence (5), stress and social status (6), learning and memory (7), eating and drinking (8), drug abuse and alcohol (9), sexual activity and hormones, pregnancy, development and endocrinology (10), mental illness and mood (11), seizures and neurologic disorders (12), electrical-related activity and neurophysiology (13), general activity and locomotion (14), gastrointestinal, renal and hepatic functions (15), cardiovascular responses (16), respiration and thermoregulation (17), and immunological responses (18).
Collapse
Affiliation(s)
- Richard J Bodnar
- Department of Psychology and Neuropsychology Doctoral Sub-Program, Queens College, City University of New York, CUNY, 65-30 Kissena Blvd., Flushing, NY, 11367, United States.
| |
Collapse
|
4
|
Long DD, Armstrong SR, Beattie DT, Campbell CB, Church TJ, Colson PJ, Dalziel SM, Jacobsen JR, Jiang L, Obedencio GP, Rapta M, Saito D, Stergiades I, Tsuruda PR, Van Dyke PM, Vickery RG. Discovery of Axelopran (TD-1211): A Peripherally Restricted μ-Opioid Receptor Antagonist. ACS Med Chem Lett 2019; 10:1641-1647. [PMID: 31857840 DOI: 10.1021/acsmedchemlett.9b00406] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2019] [Accepted: 11/06/2019] [Indexed: 12/17/2022] Open
Abstract
The effects of opioids in the central nervous system (CNS) provide significant benefit in the treatment of pain but can also lead to physical dependence and addiction, which has contributed to a growing opioid epidemic in the United States. Gastrointestinal dysfunction is an additional serious consequence of opioid use, and this can be treated with a localized drug distribution of a non-CNS penetrant, peripherally restricted opioid receptor antagonist. Herein, we describe the application of Theravance's multivalent approach to drug discovery coupled with a physicochemical property design strategy by which the N-substituted-endo-3-(8-aza-bicyclo[3.2.1]oct-3-yl)-phenyl carboxamide series of μ-opioid receptor antagonists was optimized to afford the orally absorbed, non-CNS penetrant, Phase 3 ready clinical compound axelopran (TD-1211) 19i as a potential treatment for opioid-induced constipation.
Collapse
Affiliation(s)
- Daniel D. Long
- Theravance Biopharma US, Inc., 901 Gateway Blvd., South San Francisco, California 94080, United States
| | - Scott R. Armstrong
- Theravance Biopharma US, Inc., 901 Gateway Blvd., South San Francisco, California 94080, United States
| | - David T. Beattie
- Theravance Biopharma US, Inc., 901 Gateway Blvd., South San Francisco, California 94080, United States
| | - Christina B. Campbell
- Theravance Biopharma US, Inc., 901 Gateway Blvd., South San Francisco, California 94080, United States
| | - Timothy J. Church
- Theravance Biopharma US, Inc., 901 Gateway Blvd., South San Francisco, California 94080, United States
| | - Pierre-Jean Colson
- Theravance Biopharma US, Inc., 901 Gateway Blvd., South San Francisco, California 94080, United States
| | - Sean M. Dalziel
- Theravance Biopharma US, Inc., 901 Gateway Blvd., South San Francisco, California 94080, United States
| | - John R. Jacobsen
- Theravance Biopharma US, Inc., 901 Gateway Blvd., South San Francisco, California 94080, United States
| | - Lan Jiang
- Theravance Biopharma US, Inc., 901 Gateway Blvd., South San Francisco, California 94080, United States
| | - Glenmar P. Obedencio
- Theravance Biopharma US, Inc., 901 Gateway Blvd., South San Francisco, California 94080, United States
| | - Miroslav Rapta
- Theravance Biopharma US, Inc., 901 Gateway Blvd., South San Francisco, California 94080, United States
| | - Daisuke Saito
- Theravance Biopharma US, Inc., 901 Gateway Blvd., South San Francisco, California 94080, United States
| | - Ioanna Stergiades
- Theravance Biopharma US, Inc., 901 Gateway Blvd., South San Francisco, California 94080, United States
| | - Pamela R. Tsuruda
- Theravance Biopharma US, Inc., 901 Gateway Blvd., South San Francisco, California 94080, United States
| | - Priscilla M. Van Dyke
- Theravance Biopharma US, Inc., 901 Gateway Blvd., South San Francisco, California 94080, United States
| | - Ross G. Vickery
- Theravance Biopharma US, Inc., 901 Gateway Blvd., South San Francisco, California 94080, United States
| |
Collapse
|
5
|
Mandzhulo A, Vashchenko I, Gerasov A, Vovk M, Rusanov E, Fetyukhin V, Lukin O, Shivanyuk A. Selective synthesis of N-protected exo-spiro[oxirane-3,2′-tropanes]. Org Chem Front 2019. [DOI: 10.1039/c9qo00377k] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
N-Cbz- and N-Boc-protected exo-spiro[oxirane-3,2′-tropanes] were selectively synthesized via either epoxidation or hydroxybromination/dehydrobromination of the corresponding alkenes.
Collapse
Affiliation(s)
- Aleksandr Mandzhulo
- Life Chemicals Inc
- Kyiv
- Ukraine
- Institute of Organic Chemistry
- National Academy of Sciences of Ukraine
| | | | | | - Mykhaylo Vovk
- Institute of Organic Chemistry
- National Academy of Sciences of Ukraine
- Kyiv
- Ukraine
| | - Eduard Rusanov
- Institute of Organic Chemistry
- National Academy of Sciences of Ukraine
- Kyiv
- Ukraine
| | | | | | - Alexander Shivanyuk
- Life Chemicals Inc
- Kyiv
- Ukraine
- The Institute of High Technologies
- Taras Shevchenko National University of Kyiv
| |
Collapse
|